Concepedia

Author

Sebastian Kreil

Heidelberg University

Also Known As

Kreil, Sebastian, S Kreil, S. Kreil, SEBASTIAN KREIL, Sebastian Konstantin Kreil, Sebastian Kreil

94

Publications

3.3K

Citations

24

H-Index

101

Concepts

All Affiliations

Heidelberg UniversityUniversity Hospital HeidelbergUniversity of SouthamptonUniversity Medical Centre MannheimWessex Regional Genetics Laboratory
SK

About

Sebastian Kreil is an author at Heidelberg University specializing in medicine, hematology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

14

18

1.7K

2

Health Sciences

6

6

239

3

Engineering

2

2

76

4

Management

1

1

13

5

Natural Sciences

1

1

171

Sebastian Kreil

×

42

Publications

3.2K

Citations

23

H-Index

YearCitations

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

Andreas Hochhaus, Sebastian Kreil, A. Corbin,

Leukemia

2002

900

Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms

Francis Grand, Claire Hidalgo-Curtis, Thomas Ernst,

Blood

2009

369

Response and resistance in 300 patients with BCR‐ABL–positive leukemias treated with imatinib in a single center

Tanja Lahaye, Birte Riehm, Ute Berger,

Cancer

2005

226

Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis

Celalettin Üstün, Andreas Reiter, Bart L. Scott,

Journal of Clinical Oncology

2014

181

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α

Kirsten Merx, M. C. Muller, Sebastian Kreil,

Leukemia

2002

171

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C

Martin C. Müller, Norbert Gattermann, Tanja Lahaye,

Leukemia

2003

125

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha

Amy V. Jones, Richard T. Silver, Katherine Waghorn,

Blood

2005

116

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib

Thomas Ernst, Philipp Erben, Martin Müller,

Haematologica

2008

108

Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission

Peter Paschka, Martin C. Müller, Kirsten Merx,

Leukemia

2003

92

Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia

Sebastian Kreil, Markus Pfirrmann, Claudia Haferlach,

Blood

2007

80

Page 1